Our Company
Presentation
Management Team
Board of directors
Scientific Advisory Board
Contact
Products
Tedopi®
OSE-279
Lusvertikimab (OSE-127)
Pegrizeprument (FR104)
BI 770371
ABBV-230
CLEC-1
Research & Development
Scientific publications
Investors
Press Releases
Financial documents
General Shareholders’ meetings
Regulated information
Partnerships
Pharma partnerships
Clinical partnerships
Academic and public Partnerships
News
Agenda
Press Releases
Contact
en
fr
A
u
t
h
o
r
:
A
D
M
I
N
U
S
E
R
January 2019
Article 2
January 2019
Article 3
January 2019
Article 4
January 2019
Article 5
January 2019
Article 6
January 2019
Article 7
Précédent
1
2